177662-77-0

Upstream product

• 5626-75-5 Δ^2,α-Pyrrolidinemalononitrile 
• 565178-04-3 C₁₄H₁₂N₄O 
• 103-71-9 phenyl isocyanate 

Downstream Products

• 1198113-86-8 3-amino-N-hydroxy-1-oxo-2-phenyl-1,2,4a,5,6,7-hexahydropyrrolo[1,2-c]pyrimidine-4-carboxamidine 
• 1198113-90-4 3-amino-N-amino-1-oxo-2-phenyl-1,2,4a,5,6,7-hexahydropyrrolo[1,2-c]pyrimidine-4-carboxamidine 
• 1198114-10-1 3-(4-chlorophenyl)-5-phenyl-3,4,8,9,10,10a-hexahydro-2H,5H-pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidine-1,6-dione 
• 1198114-23-6 3-(4-nitrophenyl)-5-phenyl-3,4,8,9,10,10a-hexahydro-2H,5H-pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidine-1,6-dione 
• 1198114-09-8 3,5-diphenyl-3,4,8,9,10,10a-hexahydro-2H,5H-pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidine-1,6-dione 
• 1198114-13-4 3-(4-methoxyphenyl)-5-phenyl-3,4,8,9,10,10a-hexahydro-2H,5H-pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidine-1,6-dione 
• 1198113-93-7 N-(4-cyano-1-oxo-2-phenyl-1,2,4a,5,6,7-hexahydropyrrolo-[1,2-c]pyrimidin-3-yl) formimidic acid ethyl ester 
• 1198114-21-4 3-(2-nitrophenyl)-5-phenyl-3,4,8,9,10,10a-hexahydro-2H,5H-pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidine-1,6-dione 
• 1400700-86-8 C₁₈H₁₈N₄O₄ 
• 1400700-84-6 C₁₇H₁₆N₄O₄ 
• 1400700-88-0 C₁₆H₁₄N₄O₄ 
• 1400700-92-6 C₁₆H₁₆N₆O₃ 
• 1400700-94-8 N'-benzylidene-1,6-dioxo-5-phenyl-1,2,5,6,8,9,10,10a-octahydropyrimido[5,4-e]pyrrolo[1,2-c]pyrimidine-3-carbohydrazide 
• 1400700-96-0 N'-(4-chlorobenzylidene)-1,6-dioxo-5-phenyl-1,2,5,6,8,9,10,10a-octahydropyrimido[5,4-e]pyrrolo[1,2-c]pyrimidine-3-carbohydrazide 

Relevant academic research and scientific papers

Novel heterocyclic-fused pyrimidine derivatives: Synthesis, molecular modeling and pharmacological screening

Novel heterocyclic-fused pyrimidines viz pyrrolo[1,2-c]pyrimidines 4-8, pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines 9-14, pyrimido[4′,5′:4,5] pyrimido[1,6-a]azepines 16-18, pyrrolo[1′,2′:1,6]pyrimido[4,5-d][1, 3]thiazines 19a,b and 1,3-thiazino[4′,5′:4,5]pyrimido[1,6-a]-azepine 19c were designed and synthesized as potential anticancer agents. In this investigation all the newly synthesized compounds were subjected to cytotoxic screening against MCF-7 breast cancer cell line. Moreover, kinase inhibitory assay was done for compounds 5, 7, 9 and 18 against the non-receptor and receptor tyrosine kinases c-Src and VEGFR, respectively. The tested compounds were more potent against c-Src than VEGFR, and the highest activity was observed for 18 showing 81% c-Src activity inhibition. Finally, molecular docking was performed with c-Src and VEGFR in an attempt to simulate and understand the possible binding interactions underlying the association between these small molecules and the kinase enzyme ATP binding pocket essential amino acids.

New pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines: Synthesis, 2D-QSAR, anti-inflammatory, analgesic and ulcerogenicity studies

New pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines were synthesized. A series of ylidene carbohydrazides 14a-i, and hydrazonate 15, were obtained from the prepared 3-carbohydrazide derivative 13. Pyrazole derivatives 12, 16a,b, 18, 19, 20, were also prepared through different reactions. The anti-inflammatory and analgesic activities of all new compounds were evaluated and most of them exerted comparable activity to indomethacin and celecoxib. Ulcer indexes for the most active compounds were calculated and most of them showed less ulcerogenic effect than the reference drugs. The most potent anti-inflammatory compound 12 showed an IC50 of 6.00 μmol/kg and low ulcer index. COX-1/COX-2 activity ratio of compounds 12 and 16b showed almost equal inhibitory effect on both isoenzymes. 2D-QSAR studies revealed good predictive and statistically significant QSAR models.